Haleon (LON:HLN) Given Buy Rating at Jefferies Financial Group

Jefferies Financial Group reissued their buy rating on shares of Haleon (LON:HLN) in a research note published on Monday morning,London Stock Exchange reports. They currently have a GBX 450 price objective on the stock.

Several other research analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft cut their price target on shares of Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Berenberg Bank boosted their price target on Haleon from GBX 510 to GBX 512 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 407.

Haleon Stock Performance

Haleon stock opened at GBX 376.20 on Monday. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50. The stock has a fifty day moving average price of GBX 386.06 and a 200 day moving average price of GBX 367.53. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The firm has a market capitalization of £33.51 billion, a P/E ratio of 20.34, a PEG ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last released its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 12.59% and a return on equity of 6.43%. Equities research analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.

Insiders Place Their Bets

In other Haleon news, insider Brian McNamara sold 63,012 shares of the business’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £231,884.16. 0.02% of the stock is owned by insiders.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.